Correction (DOI:10.1016/j.jaci.2006.03.045);Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

Journal of Allergy and Clinical Immunology

Volumn 118, Issue 1, 2006, Pages 152-169

  Akdis, Cezmi A ^a   Akdis, Mübeccel ^a   Bieber, Thomas ^b   Bindslev Jensen, Carsten ^c   Boguniewicz, Mark ^d,e   Eigenmann, Philippe ^f   Hamid, Qutayba ^g   Kapp, Alexander ^h   Leung, Donald Y M ^d   Lipozencic, Jasna ⁱ   Luger, Thomas A ^j   Muraro, Antonella ^k   Novak, Natalija ^b   Platts Mills, Thomas A E ^l   Rosenwasser, Lanny ^d   Scheynius, Annika ^m   Simons, F Estelle R ⁿ   Spergel, Jonathan ^o   Turjanmaa, Kristiina ^p   Wahn, Ulrich ^q   Weidinger, Stefan ^r   Werfel, Thomas ^h   Zuberbier, Torsten ^q   more..

^a SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

^g MCGILL UNIVERSITY   (Canada)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF ZAGREB   (Croatia)

^j UNIVERSITY OF MÜNSTER   (Germany)

^k UNIVERSITY OF PADOVA   (Italy)

^l Asthma and Allergic Diseases Center   (United States)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ UNIVERSITY OF MANITOBA   (Canada)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

^p TAMPERE UNIVERSITY HOSPITAL   (Finland)

^q CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^r TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

adults; Atopic dermatitis; children; diagnosis; immunopathology; risk factors; systemic treatment; topical treatment

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHEMOKINE; CHLORHEXIDINE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; EMOLLIENT AGENT; ERYTHROMYCIN; FLUTICASONE; FUSIDIC ACID; GLUCOCORTICOID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; PIMECROLIMUS; POLIDOCANOL; PREDNICARBATE; PSEUDOMONIC ACID; SALICYLIC ACID; TACROLIMUS; TRICLOSAN; UNINDEXED DRUG; UREA; WATER OIL CREAM;

ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; ATOPIC DERMATITIS; BANDAGE; BONE MARROW SUPPRESSION; BURNING SENSATION; CATARACT; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSENSUS; CONTACT ALLERGY; DERMATOLOGY; DIAGNOSTIC VALUE; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DOSE CALCULATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; EUROPE; EXPERT SYSTEM; GASTROINTESTINAL SYMPTOM; GENETIC RISK; GROUPS BY AGE; GROWTH DISORDER; HISTOPATHOLOGY; HUMAN; HYDRATION; HYPERKERATOSIS; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFANT FEEDING; INFECTION; INFECTION SENSITIVITY; INHALATION; KERATINOCYTE; LIVER TOXICITY; LONG TERM EXPOSURE; LYMPHOCYTOPENIA; MEDICAL SOCIETY; MEDICAL SPECIALIST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROORGANISM; MILK; NEPHROTOXICITY; NONHUMAN; NORTH AMERICA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT EDUCATION; PEDIATRICS; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; SKIN ATROPHY; SKIN CANCER; SKIN FUNCTION; STAPHYLOCOCCUS INFECTION; STRESS; SYMPTOMATOLOGY; T LYMPHOCYTE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 33745379354     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.07.010     Document Type: Erratum

References (200)

1. Anonymous. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 351 (1998) 1225-1232
2. Kay J., Gawkrodger D.J., Mortimer M.J., and Jaron A.G. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 30 (1994) 35-39
3. Illi S., von Mutius E., Lau S., Nickel R., Gruber C., Niggemann B., et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 113 (2004) 925-931
4. Williams H.C., and Strachan D.P. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol 139 (1998) 834-839
5. Ozkaya E. Adult-onset atopic dermatitis. J Am Acad Dermatol 52 (2005) 579-582
6. Hoffjan S., and Epplen J.T. The genetics of atopic dermatitis: recent findings and future options. J Mol Med 83 (2005) 682-692
7. Lee Y.A., Wahn U., Kehrt R., Tarani L., Businco L., Gustafsson D., et al. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet 26 (2000) 470-473
8. Cookson W.O., Ubhi B., Lawrence R., Abecasis G.R., Walley A.J., Cox H.E., et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 27 (2001) 372-373
9. Bradley M., Soderhall C., Luthman H., Wahlgren C.F., Kockum I., and Nordenskjold M. Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. Hum Mol Genet 11 (2002) 1539-1548
10. Haagerup A., Bjerke T., Schiotz P.O., Dahl R., Binderup H.G., Tan Q., et al. Atopic dermatitis-a total genome-scan for susceptibility genes. Acta Derm Venereol 84 (2004) 346-352
11. Novak N., Kruse S., Potreck J., Weidinger S., Fimmers R., and Bieber T. Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema. J Allergy Clin Immunol 115 (2005) 828-833
12. Weidinger S., Klopp N., Rümmler L., Wagenpfeil S., Novak N., Baurecht H.J., et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J Allergy Clin Immunol 116 (2005) 177-184
13. Weidinger S., Rümmler L., Klopp N., Wagenpfeil S., Baurecht H.J., Fischer G., et al. Association study of mast cell chymase polymorphisms with atopy. Allergy 60 (2005) 1256-1261
14. Laubereau B., Brockow I., Zirngibl A., Koletzko S., Gruebl A., von Berg A., et al. Effect of breast-feeding on the development of atopic dermatitis during the first 3 years of life-results from the GINI-birth cohort study. J Pediatr 144 (2004) 602-607
15. Schafer T. [Prevention of atopic eczema. Evidence based guidelines]. Hautarzt 56 (2005) 232-240
16. Capristo C., Romei I., and Boner A.L. Environmental prevention in atopic eczema dermatitis syndrome (AEDS) and asthma: avoidance of indoor allergens. Allergy 59 suppl 78 (2004) 53-60
17. Purvis D.J., Thompson J.M., Clark P.M., Robinson E., Black P.N., Wild C.J., et al. Risk factors for atopic dermatitis in New Zealand children at 3.5 years of age. Br J Dermatol 152 (2005) 742-749
18. Schafer T., Heinrich J., Wjst M., Adam H., Ring J., and Wichmann H.E. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol 104 (1999) 1280-1284
19. Eigenmann P.A., Sicherer S.H., Borkowski T.A., Cohen B.A., and Sampson H.A. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 101 (1998) e8
20. Warner J.O., and ETAC Study Group. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol 108 (2001) 929-937
21. Gustafsson D., Sjoberg O., and Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis-a prospective follow-up to 7 years of age. Allergy 55 (2000) 240-245
22. Spergel J.M., Mizoguchi E., Brewer J.P., Martin T.R., Bhan A.K., and Geha R.S. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 101 (1998) 1614-1622
23. Lack G., Fox D., Northstone K., Golding J., and Avon Longitudinal Study of Parents and Children Study Team. Factors associated with the development of peanut allergy in childhood. N Engl J Med 348 (2003) 977-985
24. Novak N., Bieber T., and Leung D.Y. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 112 suppl (2003) S128-S139
25. Leung D.Y.M., Bhan A.K., Schneeberger E.E., and Geha R.S. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol 71 (1983) 47-56
26. Novak N., Kraft S., and Bieber T. IgE receptors. Curr Opin Immunol 13 (2001) 721-726
27. Leung D.Y., Boguniewicz M., Howell M.D., Nomura I., and Hamid Q.A. New insights into atopic dermatitis. J Clin Invest 113 (2004) 651-657
28. Hamid Q., Boguniewicz M., and Leung D.Y. Differential in situ cytokine gene expression in acute versus chronic dermatitis. J Clin Invest 94 (1994) 870-876
29. Bratton D.L., Hamid Q., Boguniewicz M., Doherty D.E., Kailey J.M., and Leung D.Y. Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis. J Clin Invest 95 (1995) 211-218
30. Toda M., Leung D.Y., Molet S., Boguniewicz M., Taha R., Christodoulopoulos P., et al. Polarized in vivo expression of IL-11 and Il-17 between acute and chronic skin lesions. J Allergy Clin Immunol 111 (2003) 875-881
31. Taha R.A., Minshall E.M., Leung D.Y., Boguniewicz M., Luster A., et al. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J Allergy Clin Immunol 105 (2000) 1002-1007
32. Hijnen D., De Bruin-Weller M., Oosting B., Lebre C., De Jong E., Bruijnzeel-Koomen C., et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 113 (2004) 334-340
33. Echigo T., Hasegawa M., Shimada Y., Takehara K., and Sato S. Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. J Allergy Clin Immunol 113 (2004) 940-948
34. Klunker S., Trautmann A., Akdis M., Verhagen J., Schmid-Grendelmeier P., Blaser K., et al. A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and IFN-gamma-inducible alpha-chemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis. J Immunol 171 (2003) 1078-1084
35. Novak N., and Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 112 (2003) 252-262
36. Schmid-Grendelmeier P., Simon D., Simon H.U., Akdis C.A., and Wuthrich B. Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 56 (2001) 841-849
37. Scheynius A., Johansson C., Buentke E., Zagari A., and Linder M.T. Atopic eczema/dermatitis syndrome and Malassezia. Int Arch Allergy Immunol 127 (2002) 161-169
38. Novak N., Allam J.P., and Bieber T. Allergic hyperreactivity to microbial components: a trigger factor of "intrinsic" atopic dermatitis?. J Allergy Clin Immunol 112 (2003) 215-216
39. Kerschenlohr K., Decard S., Darsow U., Ollert M., and Wollenberg A. Clinical and immunologic reactivity to aeroallergens in "intrinsic" atopic dermatitis patients. J Allergy Clin Immunol 111 (2003) 195-197
40. Novembre E., Cianferoni A., Lombardi E., Bernardini R., Pucci N., and Vierucci A. Natural history of "intrinsic" atopic dermatitis. Allergy 56 (2001) 452-453
41. Novak N., Tepel C., Koch S., Brix K., Bieber T., and Kraft S. Evidence for a differential expression of the FcepsilonRIgamma chain in dendritic cells of atopic and nonatopic donors. J Clin Invest 111 (2003) 1047-1056
42. Sator P.G., Schmidt J.B., and Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol 48 (2003) 352-358
43. Arikawa J., Ishibashi M., Kawashima M., Takagi Y., Ichikawa Y., and Imokawa G. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol 119 (2002) 433-439
44. Rippke F., Schreiner V., Doering T., and Maibach H.I. Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus aureus. Am J Clin Dermatol 5 (2004) 217-223
45. Vasilopoulos Y., Cork M.J., Murphy R., Williams H.C., Robinson D.A., Duff G.W., et al. Genetic association between an AACC insertion in the 3′UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol 123 (2004) 62-66
46. Baud O., Goulet O., Canioni D., Le Deist F., Radford I., Rieu D., et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 344 (2001) 1758-1762
47. Spergel J.M., Mizoguchi E., Oettgen H., Bhan A.K., and Geha R.S. Roles of Th1 and Th2 cytokines in a murine model of allergic dermatitis. J Clin Invest 103 (1999) 1103-1111
48. Hoetzenecker W., Ecker R., Kopp T., Stuetz A., Stingl G., and Elbe-Burger A. Pimecrolimus leads to an apoptosis-induced depletion of T cells, but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 115 (2005) 1276-1283
49. Chan L.S., Robinson N., and Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 117 (2001) 977-983
50. Akdis M., Trautmann A., Klunker S., Daigle I., Kucuksezer U.C., Deglmann W., et al. T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. FASEB J 17 (2003) 1026-1035
51. Akdis C.A., Blaser K., and Akdis M. Apoptosis in tissue inflammation and allergic disease. Curr Opin Immunol 16 (2004) 717-723
52. Umetsu D.T., Akbari O., and Dekruyff R.H. Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol 112 (2003) 480-487
53. Akdis M., Verhagen J., Taylor A., Karamloo F., Karagiannidis C., Crameri R., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199 (2004) 1567-1575
54. Carneiro R., Reefer A., Wilson B., Hammer J., Platts-Mills J., Custis N., et al. T cell epitope-specific defects in the immune response to cat allergen in patients with atopic dermatitis. J Invest Dermatol 122 (2004) 927-936
55. Lin W., Truong N., Grossman W.J., Haribhai D., Williams C.B., Wang J., et al. Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. J Allergy Clin Immunol 116 (2005) 1106-1115
56. Ou L.S., Goleva E., Hall C., and Leung D.Y. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 113 (2004) 756-763
57. Novak N., Valenta R., Bohle B., Laffer S., Haberstok J., Kraft S., et al. FcepsilonRI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J Allergy Clin Immunol 113 (2004) 949-957
58. Wollenberg A., Wagner M., Gunther S., Towarowski A., Tuma E., Moderer M., et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 119 (2002) 1096-1102
59. Novak N., Allam J.P., Hagemann T., Jenneck C., Laffer S., Valenta R., et al. Characterization of FcepsilonRI-bearing CD123 blood dendritic cell antigen-2 plasmacytoid dendritic cells in atopic dermatitis. J Allergy Clin Immunol 114 (2004) 364-370
60. Sayama K., Komatsuzawa H., Yamasaki K., Shirakata Y., Hanakawa Y., Ouhara K., et al. New mechanisms of skin innate immunity: ASK1-mediated keratinocyte differentiation regulates the expression of beta-defensins, LL37, and TLR2. Eur J Immunol 35 (2005) 1886-1895
61. Giustizieri M.L., Mascia F., Frezzolini A., De Pita O., Chinni L.M., Giannetti A., et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 107 (2001) 871-877
62. Yoo J., Omori M., Gyarmati D., Zhou B., Aye T., Brewer A., et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 202 (2005) 541-549
63. Trautmann A., Akdis M., Kleeman D., Altznauer F., Simon H.-U., Graeve T., et al. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 106 (2000) 25-35
64. Pastore S., Corinti S., La Placa M., Didona B., and Girolomoni G. Interferon-gamma promotes exaggerated cytokine production in keratinocytes cultured from patients with atopic dermatitis. J Allergy Clin Immunol 101 (1998) 538-544
65. Trautmann A., Altznauer F., Akdis M., Simon H.-U., Disch R., Bröcker E.-B., et al. The differential fate of cadherins during T cell-induced keratinocyte apoptosis leads to spongiosis in eczematous dermatitis. J Invest Dermatol 117 (2001) 927-934
66. Trautmann A., Akdis M., Schmid-Grendelmeier P., Disch R., Bröcker E.-B., Blaser K., et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 108 (2001) 839-846
67. Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis-eosinophil granule proteins as markers of disease activity. Allergy 48 (1993) 1-5
68. Simon D., Braathen L.R., and Simon H.U. Eosinophils and atopic dermatitis. Allergy 59 (2004) 561-570
69. Schmid-Ott G., Jaeger B., Adamek C., Koch H., Lamprecht F., Kapp A., et al. Levels of circulating CD8+ T-lymphocytes, natural killer cells and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol 107 (2001) 171-177
70. Wedi B., Raap U., Lewrick H., and Kapp A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 100 (1997) 536-543
71. Grewe M., Czech W., Morita A., Werfel T., Klammer M., Kapp A., et al. Human eosinophils produce biologically active IL-12: Implications for control of T cell responses. J Immunol 161 (1998) 415-420
72. Raap U., Goltz C., Deneka N., Bruder M., Renz H., Kapp A., et al. Brain-derived neurotrophic factor is increased in atopic eczema and modulates eosinophil functions compared with that seen in nonatopic subjects. J Allergy Clin Immunol 115 (2005) 1268-1275
73. Leung D.Y., and Bieber T. Atopic dermatitis. Lancet 361 (2003) 151-160
74. Leo H.L., Bender B.G., Leung S.B., Tran Z.V., and Leung D.Y. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol 114 (2004) 691-693
75. Klein P.A., and Clark R.A. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 135 (1999) 1522-1525
76. Eichenfield L.F., Lucky A.W., Boguniewicz M., Langley R.G., Cherill R., Marshall K., et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 46 (2002) 495-504
77. Van Der Meer J.B., Glazenburg E.J., Mulder P.G., Eggink H.F., and Coenraads P.J. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 140 (1999) 1114-1121
78. Dillon S.R., Sprecher C., Hammond A., Bilsborough J., Rosenfeld-Franklin M., Presnell S.R., et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5 (2004) 752-760
79. Takaoka A., Arai I., Sugimoto M., Yamaguchi A., Tanaka M., and Nakaike S. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 516 (2005) 180-181
80. Bilsborough J., Leung D.Y., Maurer M., Howell M., Boguniewcz M., Yao L., et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 117 (2006) 418-425
81. Sonkoly E., Muller A., Lauerma A.I., Pivarcsi A., Soto H., Kemeny L., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117 (2006) 411-417
82. Toyoda M., Nakamura M., Makino T., Hino T., Kagoura M., and Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 147 (2002) 71-79
83. Sampson H.A. Update on food allergy. J Allergy Clin Immunol 113 (2004) 805-819
84. Werfel T., and Breuer K. Role of food allergy in atopic dermatitis. Curr Opin Allergy Clin Immunol 4 (2004) 379-385
85. Darsow U., Laifaoui J., Kerschenlohr K., Wollenberg A., Przybilla B., Wuthrich B., et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy 59 (2004) 1318-1325
86. Leung D.Y. Infection in atopic dermatitis. Curr Opin Pediatr 15 (2003) 399-404
87. Leung D.Y.M., Harbeck H., Bina P., Reiser R.F., Yang E., Norris A.D., et al. Presence of IgE antibodies to staphylococcal enterotoxins on the skin of patients with atopic dermatitis: evidence for a new group of allergens. J Clin Invest 92 (1993) 1374-1380
88. Hauk P.J., and Leung D.Y.M. Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis?. J Allergy Clin Immunol 107 (2001) 391-392
89. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347 (2002) 1151-1160
90. Nomura I., Goleva E., Howell M.D., Hamid Q.A., Ong P.Y., Hall C.F., et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 171 (2003) 3262-3269
91. Howell M.D., Wollenberg A., Gallo R.L., Flaig M., Streib J.E., Wong C., et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 117 (2006) 836-841
92. Plaut M., and Tinkle S.S. Risks of smallpox vaccination: 200 years after Jenner. J Allergy Clin Immunol 112 (2003) 683-685
93. Faergemann J. Pityrosporum species as a cause of allergy and infection. Allergy 54 (1999) 413-419
94. Scalabrin D.M., Bavbek S., Perzanowski M.S., Wilson B.B., Platts-Mills T.A., Wheatley L.M., et al. Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol 104 (1999) 1273-1279
95. Schmid-Grendelmeier P., Scheynius A., and Crameri R. The role of sensitization to Malassezia sympodialis in atopic eczema. Chem Immunol Allergy 91 (2006) 98-109
96. Mothes N., Niggemann B., Jenneck C., Hagemann T., Weidinger S., Bieber T., et al. The cradle of IgE hyperreactivity in atopic eczema lies in infancy. J Allergy Clin Immunol 116 (2005) 706-709
97. Natter S., Seiberler S., Hufnagl P., Binder B.R., Hirschl A.M., Ring J., et al. Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB J 12 (1998) 1559-1569
98. Valenta R., Seiberler S., Natter S., Mahler V., Mossabeb R., Ring J., et al. Autoallergy-a pathogenetic factor in atopic dermatitis. J Allergy Clin Immunol 105 (2000) 432-437
99. Schmid-Grendelmeier P., Fluckiger S., Disch R., Trautmann A., Wuthrich B., Blaser K., et al. IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol 115 (2005) 1068-1075
100. Hanifin J.M., and Rajka G. Diagnostic features of atopic eczema. Acta Dermatol Venereol (Stockh) 92 (1980) 44-47
101. Johnke H., Vach W., Norberg L.A., Bindslev-Jensen C., Host A., and Andersen K.E. A comparison between criteria for diagnosing atopic eczema in infants. Br J Dermatol 153 (2005) 352-358
102. Chatila T.A. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 116 (2005) 949-959
103. Bindslev-Jensen C., Ballmer-Weber B.K., Bengtsson U., Blanco C., Ebner C., Hourihane J., et al. Standardization of food challenges in patients with immediate reactions to foods-position paper from the European Academy of Allergology and Clinical Immunology. Allergy 59 (2004) 690-697
104. Breuer K., Heratizadeh A., Wulf A., Baumann U., Constien A., Tetau D., et al. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy 34 (2004) 817-824
105. Sampson H.A. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 107 (2001) 891-896
106. Osterballe M., and Bindslev-Jensen C. Threshold levels in food challenge and specific IgE in patients with egg allergy: is there a relationship?. J Allergy Clin Immunol 112 (2003) 196-201
107. Celik-Bilgili S., Mehl A., Verstege A., Staden U., Nocon M., Beyer K., et al. The predictive value of specific immunoglobulin E levels in serum for the outcome of oral food challenges. Clin Exp Allergy 35 (2005) 268-273
108. Turjanmaa K. The role of atopy patch tests in the diagnosis of allergy in atopic dermatitis. Curr Opin Allergy Clin Immunol 5 (2005) 425-428
109. Mitchell E.B., Crow J., Chapman M.D., Jouhal S.S., Pope F.M., and Platts-Mills T.A. Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet 1 (1982) 127-130
110. Tan B.B., Weald D., Strickland I., and Friedmann P.S. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 347 (1996) 15-18
111. Platts-Mills T.A., Mitchell E.B., Rowntree S., Chapman M.D., and Wilkins S.R. The role of dust mite allergens in atopic dermatitis. Clin Exp Dermatol 8 (1983) 233-247
112. Morren M.A., Przybilla B., Bamelis M., Heykants B., Reynaers A., and Degreef H. Atopic dermatitis: triggering factors. J Am Acad Dermatol 31 (1994) 467-473
113. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther 17 (2004) 26-34
114. Sampson H.A. Food allergy-accurately identifying clinical reactivity. Allergy 60 suppl 79 (2005) 19-24
115. Seidenari S., and Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol 75 (1996) 429-433
116. Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 4 (2003) 771-788
117. McHenry P.M., Williams H.C., and Bingham E.A. Management of atopic eczema: Joint Workshop of the British Association of Dermatologists and the Research Unit of the Royal College of Physicians of London. BMJ 310 (1995) 843-847
118. *): clinical update and current treatment strategies. Br J Dermatol 148 (2003) 3-10
119. Rudolph R., and Kownatzki E. Corneometric, sebumetric and TEWL measurements following the cleaning of atopic skin with a urea emulsion versus a detergent cleanser. Contact Dermatitis 50 (2004) 354-358
120. Darsow U., Lubbe J., Taieb A., Seidenari S., Wollenberg A., Calza A.M., et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 19 (2005) 286-295
121. Hanifin J.M., Cooper K.D., Ho V.C., Kang S., Krafchik B.R., Margolis D.J., et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines.". J Am Acad Dermatol 50 (2004) 391-404
122. Korting H.C., Kerscher M.J., and Schafer-Korting M. Topical glucocorticoids with improved benefit/risk ratio: do they exist?. J Am Acad Dermatol 27 (1992) 87-92
123. Kerscher M.J., Hart H., Korting H.C., and Stalleicken D. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 33 (1995) 187-189
124. Thomas K.S., Armstrong S., Avery A., Po A.L., O'Neill C., Young S., et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 30 (2003) 768
125. Berth-Jones J., Damstra R.J., Golsch S., Livden J.K., Van Hooteghem O., Allegra F., et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 326 (2003) 1367
126. Stalder J.F., Fleury M., Sourisse M., Rostin M., Pheline F., and Litoux P. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 131 (1994) 536-540
127. Nilsson E.J., Henning C.G., and Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 27 (1992) 29-34
128. Ainley-Walker P.F., Patel L., and David T.J. Side to side comparison of topical treatment in atopic dermatitis. Arch Dis Child 79 (1998) 149-152
129. Hultsch T., Kapp A., and Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211 (2005) 174-187
130. Wahn U., Bos J.D., Goodfield M., Caputo R., Papp K., Manjra A., et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110 (2002) e2
131. Harper J., Green A., Scott G., Gruendl E., Dorobek B., Cardno B., et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 144 (2001) 781-787
132. Ashcroft D.M., Dimmock P., Garside R., Stein K., and Williams H.C. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 330 (2005) 516
133. Luger T., Van Leent E.J., Graeber M., Hedgecock S., Thurston M., Kandra A., et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 144 (2001) 788-794
134. Paul C., Cork M., Rossi A.B., Papp K.A., Barbier N., and de Prost Y. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 117 (2006) 118-128
135. Breuer K., Werfel T., and Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 6 (2005) 65-77
136. Kempers S., Boguniewicz M., Carter E., Jarratt M., Pariser D., Stewart D., et al. A randomized inverstigator-blinded study comparing pimecrolimus cream 1% with tacrolimus 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 51 (2004) 515-525
137. Queille-Roussel C., Paul C., Duteil L., Lefebvre M.C., Rapatz G., Zagula M., et al. The new topical ascomycin derivate SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 144 (2001) 507-513
138. Wollenberg A., Zoch C., Wetzel S., Plewig G., and Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 49 (2003) 198-205
139. Elidel. [package insert] (2006), Novartis Pharmaceuticals Corp, Basel, Switzerland
140. Protopic. [package insert] (2006), Astellas Pharma Manufacturing Inc, Deerfield, Ill
141. Mallon E., Powell S., and Bridgman A. "Wet-wrap" dressings for the treatment of atopic eczema in the community. J Dermatolog Treat 5 (1994) 97-98
142. Oranje A.P., Wolkerstorfer A., and de Waard-van der Spek F.B. Treatment of erythrodermic atopic dermatitis with "wet-wrap" fluticasone propionate 0.05% cream/emollient 1:1 dressings. J Dermatolog Treat 10 (1999) 73-74
143. Foelster-Holst R., Nagel F., Zoellner P., and Spaeth D. Efficacy of crisis intervention treatment with topical corticosteroid prednicarbat with and without partial wet-wrap dressing in atopic dermatitis. Dermatology 212 (2006) 66-69
144. Boguniewicz M., and Nicol N. Conventional therapy. Immunol Allergy Clin North Am 22 (2002) 107-124
145. Breuer K., Kapp A., and Werfel T. Bacterial infections and atopic dermatitis. Allergy 56 (2001) 1034-1041
146. Breuer K., HAussler S., Kapp A., and Werfel T. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol 147 (2002) 55-61
147. Sporik R., and Kemp A.S. Topical triclosan treatment of atopic dermatitis. J Allergy Clin Immunol 99 (1997) 861
148. Bhargava H.N., and Leonard P.A. Triclosan: application and safety. Am J Infect Control 24 (1996) 209-218
149. Gauger A., Mempel M., Schekatz A., Schafer T., Ring J., and Abeck D. Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema. Dermatology 207 (2003) 15-21
150. Ricci G., Patrizi A., Bendandi B., Menna G., Varotti E., and Masi M. Clinical effectiveness of a silk fabric in the treatment of atopic dermatitis. Br J Dermatol 150 (2004) 127-131
151. Leyden J.J., and Kligman A.M. The case for steroid-antibiotic combination. Br J Dermatol 96 (1977) 179-187
152. Jappe U., Schnuch A., and Uter W. Frequency of sensitization to antimicrobials in patients with atopic eczema compared with nonatopic individuals: analysis of multicentre surveillance data, 1995-1999. Br J Dermatol 149 (2003) 87-93
153. Abeck D., and Mempel M. Staphylococcus aureus colonisation in atopic dermatitis and its therapeutic implications. Br J Dermatol 139 (1998) 13-16
154. Verbist I. The antimicrobial activity of fucidic acid. J Antimicrob Chemother 25 suppl B (1990) 1-5
155. Ravenscroft J.C., Layton A., and Barnham M. Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin Exp Dermatol 25 (2000) 327-330
156. Peeters K.A.B.M., Mascini E.M., and Sanders C.J.G. Resistance of Staphylococcus aureus to fusidic acid. Int J Dermatol 43 (2004) 235-237
157. Ravenscroft J.C., Layton A.M., Eady E.A., Murtagh M.S., Coates P., Walker M., et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. Br J Dermatol 148 (2003) 1010-1017
158. Lubbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 4 (2003) 641-654
159. Hoeger P.H. Antimicrobial susceptibility of skin-colonizing S. aureus strains in children with atopic dermatitis. Pediatr Allergy Immunol 15 (2004) 474-477
160. Boguniewicz M., Sampson H., Harbeck R., and Leung D.Y.M. Effects of cefuroxime axetil on S. aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 108 (2001) 651-652
161. Lintu P., Savolainen J., Kortekangas-Savolainen O., and Kalimo K. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy 56 (2001) 512-517
162. Baeck O., and Bartosik J. Systemic ketoconazole for yeast allergic patients with atopic dermatitis. J Eur Acad Derm Venereol 15 (2001) 34-38
163. Nikkels A.F., and Piérard G.E. Framing the future of antifungals in atopic dermatitis. Dermatology 206 (2003) 398-400
164. Aylett S.E., Atherton D.J., and Preece M.A. The treatment of difficult atopic dermatitis in childhood with oral beclomethasone dipropionate. Acta Derm Venereol Suppl 176 (1992) 123-125
165. Sowden J.M., Berth-Jones J., Ross J.S., Motley R.J., Marks R., Finlay A.Y., et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 338 (1991) 137-140
166. Berth-Jones J., Finlay A.Y., Zaki I., Tan B., Goodyear H., Lewis-Jones S., et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol 34 (1996) 1016-1021
167. Zaki I., Emerson R., and Allen B.R. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol 135 suppl 48 (1996) 21-24
168. Berth-Jones J., Graham-Brown R.A., Marks R., Camp R.D., English J.S., Freeman K., et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 136 (1997) 76-81
169. Akhavan A., and Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin Dermatol 21 (2003) 225-240
170. Anstey A.V., Wakelin S., Reynolds N.J., British Association of Dermatologists Therapy, and Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 151 (2004) 1123-1132
171. Tan B.B., Lear J.T., Gwakrdger D.J., and English J.S.C. Azathioprine in dermatology: a survey of current practice in the UK. Br J Dermatol 136 (1997) 351-355
172. Meggitt S.J., and Reynolds N.J. Azathioprine for atopic dermatitis. Clin Exp Dermatol 26 (2001) 369-375
173. Berth-Jones J., Takwale A., Tan E., Barclay G., Agarwal S., Ahmed I., et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 147 (2002) 324-330
174. Lear J.T., English J.S.C., Jones P., and Smith A.G. Retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol 35 (1996) 642-643
175. Snow J.L., and Gibson L.E. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 131 (1995) 193-197
176. Wojnarowska F., Kirtschig G., Highet A.S., Venning V.A., and Khumalo N.P. British Association of Dermatologists. Guidelines for the management of bullous pemphigoid. Br J Dermatol 147 (2002) 214-221
177. Wahlgren C.-F., Hagermark O., and Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 122 (1990) 545-551
178. Diepgen T.L., and Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 13 (2002) 278-286
179. Scheinfeld N.S., Tutrone W.D., Weinberg J.M., and DeLeo V.A. Phototherapy of atopic dermatitis. Clin Dermatol 21 (2003) 241-248
180. Abeck D., Schmidt T., Fesq H., Strom K., Mempel M., Brockow K., et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 42 (2000) 254-257
181. Krutmann J., Diepgen T.L., Luger T.A., Grabbe S., Meffert H., Sonnichsen N., et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 38 (1998) 589-593
182. Reynolds N.J., Franklin V., Gray J.C., Diffey B.L., and Farr P.M. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 357 (2001) 2012-2016
183. Mastrandrea F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Am J Clin Dermatol 5 (2004) 281-294
184. Werfel T., Breuer K., Rueff F., Przybilla B., Worm M., Grewe M., et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61 (2006) 202-205
185. Jacobi A., Antoni C., Manger B., Schuler G., and Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52 (2005) 522-526
186. Buka R.L., Resh B., Roberts B., Cunningham B.B., and Friedlander S. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 53 (2005) 358-359
187. Dimitroff C.J., Kupper T.S., and Sackstein R. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 112 (2004) 1008-1018
188. Chinn D.J., Poyner T., and Sibley G. Randomized controlled trial of a single dermatology nurse consultation in primary care on the quality of life of children with atopic eczema. Br J Dermatol 146 (2002) 432-439
189. McSkimming J., Gleeson L., and Sinclair M. A pilot study of a support group for parents of children with eczema. Australas J Dermatol 25 (1984) 8-11
190. Koblenzer C.S., and Koblenzer P.J. Chronic intractable atopic eczema. Arch Dermatol 124 (1988) 1673-1677
191. Broberg A., Kalimo K., Lindblad B., and Swanbeck G. Parental education in the treatment of childhood atopic eczema. Acta Derm Venereol 70 (1990) 495-499
192. Staab D., Ruden U., Kehrt R., and Wahn U. The impact of childhood atopic dermatitis on quality of life of family. Dermatol Psychosom 1 (2000) 173-178
193. Staab D., Diepgen T., Fartasch M., Kupfer J., Lob-Corzilius T., Ring J., et al. Age-related, structured education programmes improve the management of atopic dermatitis in children and adolescents: Results of the German Atopic Dermatitis Intervention Study (GADIS). BMJ 332 (2006) 933-938
194. Halken S., Hansen K.S., Jacobsen H.P., Estmann A., Faelling A.E., Hansen L.G., et al. Comparison of a partially hydrolyzed infant formula with two extensively hydrolyzed formulas for allergy prevention: a prospective, randomized study. Pediatr Allergy Immunol 11 (2000) 149-161
195. Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 15 suppl 16 (2004) 4-5 9-32
196. Mimouni Bloch A., Mimouni D., Mimouni M., and Gdalevich M. Does breastfeeding protect against allergic rhinitis during childhood? A meta-analysis of prospective studies. Acta Paediatr 91 (2002) 275-279
197. Muraro A., Dreborg S., Halken S., Host A., Niggemann B., Aalberse R., et al. Dietary prevention of allergic diseases in infants and small children. Part III: critical review of published peer-reviewed observational and interventional studies and final recommendations. Pediatr Allergy Immunol 15 (2004) 291-307
198. von Berg A., Koletzko S., Grubl A., Filipiak-Pittroff B., Wichmann H.E., Bauer C.P., et al. The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double-blind trial. J Allergy Clin Immunol 111 (2003) 533-540
199. Muraro A., Dreborg S., Halken S., Host A., Niggemann B., Aalberse R., et al. Dietary prevention of allergic diseases in infants and small children. Part II. Evaluation of methods in allergy prevention studies and sensitization markers. Definitions and diagnostic criteria of allergic diseases. Pediatr Allergy Immunol 15 (2004) 196-205
200. Isolauri E., Arvola T., Sutas Y., Moilanen E., and Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy 30 (2000) 1604-1610